Momenta Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc.

MNTA 52.48

0.0%

Oct 2 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mopgcw who wrote (2838)	9/24/2011 2:20:40 PM
From: Kaalia	1 Recommendation of 3027

Believe they will still end up with about 100m$ rev. & 80m$ costs = 20m$ cash flow per annum i.e. around 0.4$/ share. hence 0.4$/ share x 5 = 2$/ share + 7$/ share end of the year cash. there you go... approx. 9$/ share imminent value unless someone can fire the management to focus on r&D of 80m$ only if something productive comes out of it. Shea at UBS mentioned that 80m$ p.a. of cash burn is not going to change until launch of copaxone generic version in 2014 which WILL happen though. Hence if optimized R&D then i would agree with 17$/ share straight forward valuation. + upside on Copaxone would give another 3-5$/ share hence we are looking at a stock which by Q3'2013 will be $20-$22/ share by pure fundamentals. Priority for management - 1. Avoid launch of Watson to prolong the cash flow via legal means 2. Cut down highly non-productive R&D (not a single REAL new molecule so far.. not even in Phase 2) 3. Reshape the self rewarding managment that is buring a hole with stock op rewards.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next